在慢性心力衰竭患者中,阿波蛋白A-I水平与预后有关,特别是在HFmrEF和HFpEF:回顾性队列研究中
XueChun He1, FaPeng Li2, Jian Zhang1
1Department of Cardiology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830054, People's Republic of China.
International journal of general medicine
|September 2, 2025
概括
在慢性心力衰竭 (CHF) 患者中,低的ApoA- I水平预测了全因死亡率 (ACM) 的增加. 这种关联在心力衰竭中具有显著意义,其中包括中等范围心力衰竭 (HFmrEF) 和保留射出分数心力衰竭 (HFpEF) 亚型.
科学领域:
- 心脏病学
- 生物标志物
- 预测情况
背景情况:
- 慢性心力衰竭 (CHF) 在全球造成重大健康负担.
- 确定可靠的预后标志物对于治疗心脏病患者至关重要.
- 脂蛋白A-I (ApoA-I) 是高密度脂蛋白 (HDL) 的一个关键组成部分,在逆胆固醇运输中起作用.
研究的目的:
- 在慢性心力衰竭 (CHF) 患者中研究阿波利波蛋白A- I (ApoA- I) 的预测价值和预后意义.
- 评估不同CHF亚型的ApoA- I水平与全因死亡率 (ACM) 之间的关联.
主要方法:
- 一组4442名心血管衰竭患者的平均持续时间为22. 75个月.
- 根据ROC曲线分析,患者被分为低和高的ApoA- I组.
- 用多变量考克斯回归分析来确定ACM的风险.
主要成果:
- 在整体CHF队列中,较低的ApoA- I水平与增加的ACM风险显著相关 (HR=0. 702,P < 0. 001).
- 这种关联在心力衰竭患者中具有中等射出分数 (HFmrEF) (HR=0. 443,P < 0. 001) 和心力衰竭患者中具有保留射出分数 (HFpEF) (HR=0. 704,P = 0. 010) 中仍然显著.
- 在心力衰竭患者中,没有发现ApoA- I水平与ACM之间的显著关联 (HR=0. 806,P=0. 194).
结论:
- 在CHF患者中,Apolipoprotein A- I度与所有原因的死亡率有显著的关联.
- 在HFmrEF和HFpEF中,ApoA- I的预后价值尤其显著.
- 在特定的CHF群体中,ApoA-I可作为一种有价值的生物标志物.
更多相关视频
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
9.4K
04:05Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
2.2K
相关概念视频
01:30Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
01:17Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
01:27Heart Failure I: Introduction
52
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
52
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27